At BD, our commitment to patients extends beyond selling innovative product solutions—we are also passionate about expanding the breadth and depth of the physician’s practices to support the delivery of patient care through our comprehensive and wide-ranging approaches. Our portfolio includes more than 100 different training events this year that are focused on end-stage kidney disease (ESKD) education for the multidisciplinary treatment team (nephrology, interventionalists, surgeons, ultrasound technicians, and dialysis nurses and technicians).

Our ADVANCE Professional Development and Clinical Education programs in the area of ESKD and the important element of vascular access support physicians’ professional growth by providing shoulder-to-shoulder training with globally recognized experts and collaborators using innovative interventional tools, such as FLUENCY® PLUS Endovascular Stent Graft, COVERA™ Vascular Covered Stent, and LUTONIX® 035 Drug Coated Balloon PTA Catheter, which are designed to address the frequent and challenging lesions in the arteriovenous (AV) circuit.

We also offer training on how to create an endovascular AV fistula (endoAVF) using a catheter-based system as an additional option to surgical creation. Our WAVELINQ™ 4F EndoAVF System training, partnering with world-class Centers of Excellence around the country, utilizes innovative procedural simulations and learning programs to provide exceptional peer-to-peer clinical discussions and practical hands-on experience. The WAVELINQ™ 4F EndoAVF System consists of using two thin, flexible magnetic catheters inserted in adjacent blood vessels in the arm, and after a small burst of radiofrequency energy, an endovascular fistula is created. This training program extends beyond the procedural aspects of fistula creation, including education on patient selection for ultrasound technicians during vascular mapping and supporting dialysis centers on cannulation of this new endovascular fistula.

Our dedication to restoration and maintenance of the AV access circuit is demonstrated through our comprehensive educational programs that are designed to help you as clinicians deliver exceptional patient care across the entire disease state, which in turn, helps your patients.

—JD Meler, MD
VP, Medical & Clinical Affairs
BD Peripheral Intervention

BD-10848


In August 2019, the U.S. Food and Drug Administration (FDA) issued an updated letter to health care providers noting an increased risk in late mortality (2-3 years post-treatment) with paclitaxel-coated devices when used to treat peripheral arterial disease in the femoropopliteal artery as compared with the use of non-drug coated devices. There is uncertainty regarding the magnitude and mechanism for the increased late mortality risk, including the impact of repeat paclitaxel-coated device exposure. Physicians should discuss this late mortality signal and the benefits and risks of available treatment options with their patients. BD will continue to work collaboratively with FDA and industry for additional safety data collection and inform labeling as appropriate. These communications as well as information about the FDA Panel meeting can be found at: https://www.fda.gov/medical-devices/letters-health-care-providers/august-7-2019-update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel.

All authors of this supplement were compensated by BD.